[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367361-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367361-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeting-ncrnas-to-overcome-metabolic-reprogramming-mediated-drug-resistance-in-cancer-review","Targeting ncRNAs to overcome metabolic reprogramming-mediated drug resistance in cancer - Review","","Resistance of cancer cells to antitumor drugs creates a major obstacle in cancer therapy. Metabolic reprogramming involves increased glycolysis, impaired lipid metabolism, glutamine dependence, and mitochondrial dysfunction, and it can enable drug resistance via multiple molecular mechanisms while also promoting growth and metastasis. Non-coding RNAs (ncRNAs), which do not encode proteins, influence cancer pathophysiology through distinct expression patterns and regulatory functions. This review analyzes how metabolic reprogramming drives resistance and highlights ncRNA roles in glycolysis, lipid metabolism, mitochondrial dysfunction, and glutamine metabolism, including biomarker potential and emerging ncRNA-targeting strategies in combination therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeting-ncrnas-to-overcome-metabolic-reprogramming-mediated-drug-resistance-in-cancer-review/367361/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeting-ncrnas-to-overcome-metabolic-reprogramming-mediated-drug-resistance-in-cancer-review/367361.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What metabolic reprogramming features are linked to drug resistance in cancer cells?","Question",{"text":63,"@type":64},"The review links drug resistance to enhanced glycolysis, disrupted lipid metabolism, glutamine dependence, and mitochondrial dysfunction, which together support tumor survival under treatment pressure.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do non-coding RNAs contribute to metabolic regulation related to drug resistance?",{"text":68,"@type":64},"ncRNAs regulate metabolic abnormalities tied to drug resistance by controlling pathways associated with glycolysis, lipid metabolism, mitochondrial function, and glutamine metabolism.",{"name":70,"@type":61,"acceptedAnswer":71},"What potential clinical roles do ncRNAs have according to the review?",{"text":72,"@type":64},"The review discusses ncRNAs as candidate biomarkers for predicting chemotherapy responses and as emerging therapeutic targets, especially within combination therapy strategies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367361,1790593066,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","INTERNATIONAL JOURNAL OF ONCOLOGY 66: 35, 2025  \nTargeting ncRNAs to overcome metabolic reprogramming‑mediated drug resistance in cancer (Review)  \nJUNXIN LI 1 , YANYU LI 1 , LIN FU 1 , HUILING CHEN 1 , FEI DU2 , ZHONGSHU WANG 1 , YAN ZHANG 1 , YU HUANG 1 , JIDONG MIAO3 and YI XIAO 1  \n1 2  \nDepartment of Pharmacy, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China; Department of Pharmacy, The Fourth Affiliated Hospital of Southwest Medical University, Meishan, Sichuan 64200, P.R. China;  \n3  \nDepartment of Oncology, Zigong Fourth People's Hospital, Zigong, Sichuan 643000, P.R. China  \nReceived January 22, 2025; Accepted March 7, 2025  \nDOI: 10.3892/ijo.2025.5741  \nAbstract. The emergence of resistance to antitumor drugs in cancer cells presents a notable obstacle in cancer therapy. Metabolic reprogramming is characterized by enhanced glycolysis, disrupted lipid metabolism, glutamine dependence and mitochondrial dysfunction . In addition to promoting tumor growth and metastasis, metabolic repro‑ gramming mediates drug resistance through diverse molecular mechanisms, offering novel opportunities for therapeutic intervention . Non‑coding RNAs (ncRNAs), a diverse class of RNA molecules that lack protein‑coding function, represent a notable fraction of the human genome. Due to their distinct expression profiles and multifaceted roles in various cancers, ncRNAs have relevance in cancer pathophysiology. ncRNAs orchestrate metabolic abnor‑ malities associated with drug resistance in cancer cells . The present review provides a comprehensive analysis of the mechanisms by which metabolic reprogramming drives drug resistance, with an emphasis on the regulatory roles of ncRNAs in glycolysis, lipid metabolism, mitochondrial dysfunction and glutamine metabolism . Furthermore, the present review aimed to discuss the potential of ncRNAsas biomarkers for predicting chemotherapy responses, as well as emerging strategies to target ncRNAs that modu‑ late metabolism, particularly in the context of combination therapy with anti‑cancer drugs.  \nCorrespondence to: Professor Yi Xiao, Department of Pharmacy, Zigong Fourth People's Hospital, 19 Tanmulin Street, Zigong, Sichuan 643000, P.R. China  \nE‑mail: [4705700@qq.com](4705700@qq.com)  \nProfessor Jidong Miao, Department of Oncology, Zigong Fourth People's Hospital, 19 Tanmulin Street, Zigong, Sichuan 643000, P.R. China  \nE‑[mail: miaojidong@126.com](mail: miaojidong@126.com)  \nKey words: non‑coding RNA, glycolysis, lipid metabolism, ferroptosis, mitochondrion, glutamine, drug‑resistant  \nContents  \n1. Introduction  \n2. ncRNAs regulate drug resistance by mediating metabolic reprogramming  \n3. Cancer‑type‑specific ncRNA networks  \n4. Clinical application  \n5. Discussion and perspectives  \n6. Conclusion  \n1. Introduction  \nCancer is the second leading cause of global mortality, with~20 million cases and 9.7 million deaths reported in 2022 (1) . While therapeutic strategies such as surgical resection, chemo‑ therapy, radiotherapy, targeted therapy and immunotherapy have advanced, drug resistance and adverse reactions under‑ mine clinical outcomes (2,3) . Drug resistance not only drives tumor recurrence but also perpetuates cancer as a key public health challenge (4) .  \nCurrent investigations into therapy resistance mechanisms extend beyond ATP‑binding cassette (ABC) transporter‑medi‑ ated drug efflux to encompass metabolic reprogramming, exemplified by the Warburg effect, alongside dynamic mito‑ chondrial interactions (5,6) . Cancer cells exhibit a range of metabolic adaptations, enabling them to secure energy despite limited nutrient and oxygen availability (7) . In the 1920s, Otto Warburg demonstrated that cancer cells preferentially generate ATP through glycolysis, even in the presence of sufficient oxygen (8) . Research on cancer cell metabolism primarily focuses on glycolysis, glutamine metabolism and mitochon‑ drial protective mechanisms (9,10) . Moreover, abnormal lipid metaboli","cbCaieaal3uPYK4J","https://ap.wps.com/l/cbCaieaal3uPYK4J","pdf",3470059,29,"English","# 1. Introduction\n## 2. ncRNAs regulate drug resistance by mediating metabolic reprogramming\n## 3. Cancer-type-specific ncRNA networks\n## 4. Clinical application\n## 5. Discussion and perspectives\n## 6. Conclusion","[{\"question\":\"What metabolic reprogramming features are linked to drug resistance in cancer cells?\",\"answer\":\"The review links drug resistance to enhanced glycolysis, disrupted lipid metabolism, glutamine dependence, and mitochondrial dysfunction, which together support tumor survival under treatment pressure.\"},{\"question\":\"How do non-coding RNAs contribute to metabolic regulation related to drug resistance?\",\"answer\":\"ncRNAs regulate metabolic abnormalities tied to drug resistance by controlling pathways associated with glycolysis, lipid metabolism, mitochondrial function, and glutamine metabolism.\"},{\"question\":\"What potential clinical roles do ncRNAs have according to the review?\",\"answer\":\"The review discusses ncRNAs as candidate biomarkers for predicting chemotherapy responses and as emerging therapeutic targets, especially within combination therapy strategies.\"}]","Targeting ncRNAs to overcome metabolic reprogramming-mediated drug resistance in cancer - Review | PDF",1790170476,73,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ef4cf202f343adb210504b12af60c9d.webp",983,1357,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/400294859cd0ef760935b1fe709b83fa.webp",982,1356,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/799bb71859d72082b1ddeb9a350e9c13.webp",981,1354,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/404f7b2af9561c1a330be08be642ca63.webp",980,1353]